Use of implantable cardioverter-defibrillator in children supported with ventricular assist device: An analysis of data from the EUROMACS registry.


Journal

Artificial organs
ISSN: 1525-1594
Titre abrégé: Artif Organs
Pays: United States
ID NLM: 7802778

Informations de publication

Date de publication:
Aug 2023
Historique:
revised: 14 02 2023
received: 08 12 2022
accepted: 24 02 2023
medline: 5 9 2023
pubmed: 2 3 2023
entrez: 1 3 2023
Statut: ppublish

Résumé

Data on the use and outcome of children on ventricular assist device (VAD) support provided with an implantable cardioverter-defibrillator (ICD) remains poor. A retrospective analysis of the EUROMACS database on children supported with VAD < 19 years of age from January 1, 2009 to April 1, 2020. Patients with missing data on status of ICD, missing baseline and/or follow up information were excluded. The primary independent variable of interest was the concomitant presence or absence of an ICD at the time of VAD placement. Kaplan-Meier survival analysis was performed to evaluate survival differences between children on VAD with and without an ICD. Out of 303 patients provided with a VAD, 7% (7♀, 15♂) had an ICD implanted and formed the study group. Median age was 14 years, median weight was 43.5 kg, and median BSA was 1.39. Median Intermacs stage was 2 (range: 1-7). Seventeen patients (77%) were transplanted, 4 (18%) died while on support, and 1 (5%) was weaned from device after myocardial recovery. Median time on support was 68 days compared to 361 days in the control group (p: 0.01). Three patients underwent device exchange due to thrombus formation in the pump. There was no difference in survival between groups (p = 0.342). The presence of ICD in pediatric patients supported with a VAD is low (7%). Children on VAD support provided with an ICD do not have a survival benefit compared to children without an ICD.

Sections du résumé

BACKGROUND BACKGROUND
Data on the use and outcome of children on ventricular assist device (VAD) support provided with an implantable cardioverter-defibrillator (ICD) remains poor.
METHODS METHODS
A retrospective analysis of the EUROMACS database on children supported with VAD < 19 years of age from January 1, 2009 to April 1, 2020. Patients with missing data on status of ICD, missing baseline and/or follow up information were excluded. The primary independent variable of interest was the concomitant presence or absence of an ICD at the time of VAD placement. Kaplan-Meier survival analysis was performed to evaluate survival differences between children on VAD with and without an ICD.
RESULTS RESULTS
Out of 303 patients provided with a VAD, 7% (7♀, 15♂) had an ICD implanted and formed the study group. Median age was 14 years, median weight was 43.5 kg, and median BSA was 1.39. Median Intermacs stage was 2 (range: 1-7). Seventeen patients (77%) were transplanted, 4 (18%) died while on support, and 1 (5%) was weaned from device after myocardial recovery. Median time on support was 68 days compared to 361 days in the control group (p: 0.01). Three patients underwent device exchange due to thrombus formation in the pump. There was no difference in survival between groups (p = 0.342).
CONCLUSION CONCLUSIONS
The presence of ICD in pediatric patients supported with a VAD is low (7%). Children on VAD support provided with an ICD do not have a survival benefit compared to children without an ICD.

Identifiants

pubmed: 36855905
doi: 10.1111/aor.14515
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1319-1325

Informations de copyright

© 2023 International Center for Artificial Organ and Transplantation (ICAOT) and Wiley Periodicals LLC.

Références

Cantillon DJ, Tarakji KG, Kumbhani DJ, Smedira NG, Starling RC, Wilkoff BL. Improved survival among ventricular assist device recipients with a concomitant implantable cardioverter-defibrillator. Heart Rhythm. 2010;7:466-71.
Cikes M, Jakus N, Claggett B, Brugts JJ, Timmermans P, Pouleur AC, et al. Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry. Eur J Heart Fail. 2019;21:1129-41.
Clerkin KJ, Topkara VK, Demmer RT, Dizon JM, Yuzefpolskaya M, Fried JA, et al. Implantable cardioverter-defibrillators in patients with a continuous-flow left ventricular assist device: an analysis of the INTERMACS registry. JACC Heart Fail. 2017;5:916-26.
Vakil K, Kazmirczak F, Sathnur N, Adabag S, Cantillon DJ, Kiehl EL, et al. Implantable cardioverter-defibrillator use in patients with left ventricular assist devices: a systematic review and meta-analysis. JACC Heart Fail. 2016;4:772-9.
Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, et al. The 2013 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013;32:157-87.
Potapov EV, Antonides C, Crespo-Leiro MG, Combes A, Farber G, Hannan MM, et al. 2019 EACTS expert consensus on long-term mechanical circulatory support. Eur J Cardiothorac Surg. 2019;56:230-70.
Silvetti MS. Cardioverter-defibrillator in children and young patients with congenital heart disease. Time to define ICD selection. Kardiol Pol. 2020;78:839-41.
Berul CI, Van Hare GF, Kertesz NJ, Dubin AM, Cecchin F, Collins KK, et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol. 2008;51:1685-91.
Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the Management of Patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36:2793-867.
Writing Committee M, Shah MJ, Silka MJ, Silva JNA, Balaji S, Beach CM, et al. 2021 PACES expert consensus statement on the indications and Management of Cardiovascular Implantable Electronic Devices in pediatric patients: developed in collaboration with and endorsed by the Heart Rhythm Society (HRS), the American College of Cardiology (ACC), the American Heart Association (AHA), and the Association for European Paediatric and Congenital Cardiology (AEPC) endorsed by the Asia Pacific Heart Rhythm Society (APHRS), the Indian Heart Rhythm Society (IHRS), and the Latin American Heart Rhythm Society (LAHRS). JACC Clin Electrophysiol. 2021;7:1437-72.
de By T, Antonides CFJ, Schweiger M, Sliwka J, Davies B, Berger F, et al. The European registry for patients with mechanical circulatory support (EUROMACS): second EUROMACS Paediatric (Paedi-EUROMACS) report. Eur J Cardiothorac Surg. 2020;57:1038-50.
de By T, Schweiger M, Waheed H, Berger F, Hubler M, Ozbaran M, et al. The European registry for patients with mechanical circulatory support (EUROMACS): first EUROMACS Paediatric (Paedi-EUROMACS) report. Eur J Cardiothorac Surg. 2018;54:800-8.
Morales DLS, Adachi I, Peng DM, Sinha P, Lorts A, Fields K, et al. Fourth annual pediatric interagency registry for mechanical circulatory support (Pedimacs) report. Ann Thorac Surg. 2020;110:1819-31.
de By T, Schweiger M, Hussain H, Amodeo A, Martens T, Bogers A, et al. The European registry for patients with mechanical circulatory support (EUROMACS): third Paediatric (Paedi-EUROMACS) report. Eur J Cardiothorac Surg. 2022;62:ezac355.
de By T, Schoenrath F, Veen KM, Mohacsi P, Stein J, Alkhamees KMM, et al. The European registry for patients with mechanical circulatory support of the European Association for Cardio-Thoracic Surgery: third report. Eur J Cardiothorac Surg. 2022;62:ezac032.
Von Bergen NH, Atkins DL, Dick M 2nd, Bradley DJ, Etheridge SP, Saarel EV, et al. Multicenter study of the effectiveness of implantable cardioverter defibrillators in children and young adults with heart disease. Pediatr Cardiol. 2011;32:399-405.
Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA 3rd, et al. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;61:1527-35.
Norrish G, Ding T, Field E, McLeod K, Ilina M, Stuart G, et al. A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy. Europace. 2019;21:1559-65.
Link MS, Hill SL, Cliff DL, Swygman CA, Foote CB, Homoud MK, et al. Comparison of frequency of complications of implantable cardioverter-defibrillators in children versus adults. Am J Cardiol. 1999;83:263-6. A5-6.
Kirkfeldt RE, Johansen JB, Nohr EA, Jorgensen OD, Nielsen JC. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J. 2014;35:1186-94.
Winkler F, Dave H, Weber R, Gass M, Balmer C. Long-term outcome of epicardial implantable cardioverter-defibrillator systems in children: results justify its preference in paediatric patients. Europace. 2018;20:1484-90.
Korte T, Koditz H, Niehaus M, Paul T, Tebbenjohanns J. High incidence of appropriate and inappropriate ICD therapies in children and adolescents with implantable cardioverter defibrillator. Pacing Clin Electrophysiol. 2004;27:924-32.
Alexander ME, Cecchin F, Walsh EP, Triedman JK, Bevilacqua LM, Berul CI. Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics. J Cardiovasc Electrophysiol. 2004;15:72-6.
Atallah J, Erickson CC, Cecchin F, Dubin AM, Law IH, Cohen MI, et al. Multi-institutional study of implantable defibrillator Lead performance in children and young adults: results of the pediatric Lead extractability and survival evaluation (PLEASE) study. Circulation. 2013;127:2393-402.
Korte T, Jung W, Spehl S, Wolpert C, Moosdorf R, Manz M, et al. Incidence of ICD lead related complications during long-term follow-up: comparison of epicardial and endocardial electrode systems. Pacing Clin Electrophysiol. 1995;18:2053-61.
Eicken A, Kolb C, Lange S, Brodherr-Heberlein S, Zrenner B, Schreiber C, et al. Implantable cardioverter defibrillator (ICD) in children. Int J Cardiol. 2006;107:30-5.
Sears SF, Conti JB. Implantable cardioverter-defibrillators for children and young adolescents: mortality benefit confirmed - what's next? Heart. 2004;90:241-2.

Auteurs

Martin Schweiger (M)

Department of Congenital Cardiovascular Surgery, Pediatric Heart Center, University Children's Hospital Zurich, Zürich, Switzerland.
Children's Research Center, University Children's Hospital Zurich, Zürich, Switzerland.

Antonio Amodeo (A)

Children's Research Center, University Children's Hospital Zurich, Zürich, Switzerland.
Clinic of Cardiac Surgery, University Heart Center, University Hospital Zurich, Zürich, Switzerland.

Juliane Vierecke (J)

University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

Hina Hussein (H)

Quality and Outcomes Research Unit, University Hospital Birmingham, Birmingham, UK.

Florian Berger (F)

Children's Research Center, University Children's Hospital Zurich, Zürich, Switzerland.
Division Pediatric Cardiology, Pediatric Heart Center, University Children's Hospital Zurich, Zürich, Switzerland.

Theo M M H de By (TMMH)

EUROMACS, EACTS House, Windsor, UK.

Daniel Zimpfer (D)

Department for Heart Surgery, Medical University Graz, Graz, Austria.

Joanna Sliwka (J)

Department of Cardiac Surgery, Transplantology and Vascular Surgery, Silesian Center for Heart Diseases, Zabrze, Poland.

Ben Davies (B)

Royal Children's Hospital, Melbourne, Victoria, Australia.

Oliver Miera (O)

German Heart Institute Berlin, Berlin, Germany.

Bart Meyns (B)

Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium., Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH